KROS
Keros Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 18 to Feb 19 ▼ 2 days of insider sells: $331.8K by 4 insiders, avg $16.29
- Mar 9 ▲ 1 insider buy $22.4K at $11.21
- Apr 15 ▲ 1 insider buy $11.7K at $11.70
- May 15 ▲ 1 insider buy $10.6K at $10.58
- Jun 4 to Jun 11 ▼ 2 days of insider sells: $90.0K by 4 insiders, avg $10.68
- Jun 15 ▲ 1 insider buy $10.2K at $10.19
- Jul 15 ▲ 1 insider buy $10.6K at $10.61
- Aug 17 ▲ 1 insider buy $10.3K at $10.27
- Aug 18 ▼ 4 insiders sell $101.1K at $10.29
- Sep 8 Contract: Keros Therapeutics Announces $5 Million Share Repurchase A…
- Sep 28 FDA: Keros Therapeutics Announces the First Patient Dosing in t…
- Sep 29 ▲ Keros Therapeutics announced a $20 million development milestone pay…
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $75.8K at an average $10.82. 9 insiders sold $522.9K. Price is 7% below their cost.
- InstitutionsMIXED
Q3 2026: 18 added (0 new), 15 trimmed or exited.
- Short sellersSTEADY
Short interest −4.5% to 1.09M shares. 7.1 days to cover, ≈5.5% of shares.
- TrendDOWNTREND
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $39.9M |
| Qube Research & Technologies Ltd | TRIM | $5.0M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | $2.0M |
| MORGAN STANLEY | ADD | $1.5M |
| MARSHALL WACE, LLP | DOUBLED | $1.3M |
| Quantinno Capital Management LP | DOUBLED | $1.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $906.3K |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $822.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026| Date | Firm | Rating |
|---|---|---|
| Aug 4, 2026 | Wells Fargo MAINTAIN | Overweight |
| Aug 4, 2026 | Leerink Partners MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Newton Charles W. Director Aug 18, 2026 | SELL | $5.7K |
Tanini Annita Corp. Controller & VP, Finance Aug 18, 2026 | SELL | $12.6K |
Cho Esther Chief Legal Officer Aug 18, 2026 | SELL | $46.2K |
Lerner Lorena Raquel Chief Scientific Officer Aug 18, 2026 | SELL | $36.7K |
BIENAIME JEAN JACQUES Director Aug 17, 2026 | BUY | $10.3K |
BIENAIME JEAN JACQUES Director Jul 15, 2026 | BUY | $10.6K |
Prener Anne Director Jul 1, 2026 | AWARD | 14,870 sh |
Prener Anne Director Jul 1, 2026 | AWARD | 13,786 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
23 filings · 4 press releases · 2 bullish · 2 bearish · 2 mixed · 17 neutral- NEUTRAL PRESS RELEASENov 16, 2026
Keros Therapeutics announced a $5 million share repurchase program, funded by a $20 million development milestone payment from Takeda under the elritercept license agreement, triggered by dosing the first patient in the ELRiSE MF clinical trial. The buyback is small relative to the company's $198M…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Director Anne Prener filed a Form 144 notice of intent to sell 574 shares of Keros Therapeutics…
The proposed sale is de minimis and likely part of routine portfolio management. Monitor for any subsequent Form 4 filings to confirm execution, but no material impact is expected.
- NEUTRAL 8-KNov 5, 2026
Keros Therapeutics filed an 8-K to update its corporate presentation, which is used in investor…
Monitor for initial Phase 2 rinvatercept data in DMD expected in H1 2027 and regulatory engagement for the ALS trial design. The Takeda partnership milestones for elritercept remain a key value…
- NEUTRAL 8-KNov 5, 2026
Keros Therapeutics reported Q3 2026 net income of $14.2 million, a significant swing from a net…
The Takeda license revenue is non-recurring; the core operating loss (R&D + G&A of $27.2M) continues. Monitor the Phase 2 rinvatercept data expected in H1 2027 and the cash burn rate to assess the…
All KROS filing & press-release reports (27)
- PRESS-RELEASE reportNov 16, 2026
- 144 reportNov 12, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- SC 13G/A reportOct 27, 2026
- 8-K reportSep 29, 2026
- 8-K reportSep 28, 2026
- PRESS-RELEASE reportSep 28, 2026
- EFFECT reportSep 17, 2026
- 8-K reportSep 8, 2026
- CLUSTER reportAug 20, 2026
- 8-K reportAug 3, 2026
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJul 30, 2026
- 8-K reportJul 22, 2026
- CLUSTER reportJun 17, 2026
- CLUSTER reportJun 8, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- DEFA14A reportApr 22, 2026
- 144 reportMar 31, 2026
- PRESS-RELEASE reportMar 9, 2026
- 8-K reportMar 4, 2026
- 8-K reportMar 4, 2026
- PRESS-RELEASE reportMar 4, 2026
- INST-CLUSTER reportFeb 28, 2026